This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Prognosis

Authoring team

Despite supportive measures, in-hospital mortality from ARDS remains high, varying with hypoxaemia severity (from 35% in mild ARDS to 46% in severe ARDS in the LUNG-SAFE cohort).

Factors influencing prognosis:

  • mortality has declined in clinical trials over time, although community-based studies indicate persistently high mortality
  • coexisting multiorgan failure, frailty, chronic liver disease, and cancer are major determinants of poor outcome
  • biologic subphenotypes also carry distinct prognoses, with mortality approximately twice as high in the hyperinflammatory subphenotype compared with the hypoinflammatory subphenotype

Long-term outcomes in survivors:

  • most survivors recover normal or near-normal pulmonary function rather than universal residual respiratory disability
  • however, persistent functional disability, exercise limitation, reduced quality of life, and psychological and mental health sequelae can persist for up to 5 years after diagnosis

Reference:

  1. Calfee CS, McAuley DF. Acute Respiratory Distress Syndrome. N Engl J Med. 2026;395(20):2027-2042. doi:10.1056/NEJMra2601172.

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page